Rhumbline Advisers cut its stake in shares of Allergan plc (NYSE:AGN) by 4.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 511,143 shares of the company’s stock after selling 23,371 shares during the quarter. Rhumbline Advisers owned 0.15% of Allergan worth $97,363,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AGN. Thompson Siegel & Walmsley LLC boosted its stake in shares of Allergan by 3,032.4% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 877,740 shares of the company’s stock worth $146,337,000 after acquiring an additional 849,719 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Allergan by 27,066.5% during the 2nd quarter. Renaissance Technologies LLC now owns 787,828 shares of the company’s stock worth $131,347,000 after acquiring an additional 784,928 shares in the last quarter. Sound Shore Management Inc. CT bought a new stake in shares of Allergan during the 3rd quarter worth $140,026,000. Mainstay Capital Management LLC ADV boosted its stake in shares of Allergan by 13,097.2% during the 2nd quarter. Mainstay Capital Management LLC ADV now owns 675,039 shares of the company’s stock worth $4,288,000 after acquiring an additional 669,924 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Allergan by 16.3% during the 2nd quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock worth $796,712,000 after acquiring an additional 668,343 shares in the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

In related news, Director Christopher J. Coughlin bought 10,000 shares of the business’s stock in a transaction on Thursday, September 6th. The shares were bought at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Joseph H. Boccuzi bought 900 shares of the business’s stock in a transaction on Thursday, August 30th. The shares were bought at an average price of $190.59 per share, for a total transaction of $171,531.00. The disclosure for this purchase can be found here. 0.37% of the stock is owned by company insiders.

Several equities research analysts have recently weighed in on the company. Leerink Swann assumed coverage on Allergan in a research note on Monday. They set an “outperform” rating and a $220.00 price objective for the company. Wells Fargo & Co reissued a “buy” rating on shares of Allergan in a research note on Wednesday, October 31st. Raymond James reduced their price objective on Allergan from $232.00 to $198.00 and set a “buy” rating for the company in a research note on Wednesday, October 31st. Credit Suisse Group reduced their price objective on Allergan from $213.00 to $202.00 and set an “outperform” rating for the company in a research note on Wednesday, October 31st. Finally, Cowen set a $255.00 price objective on Allergan and gave the stock a “buy” rating in a research note on Tuesday, October 30th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $209.18.

Shares of NYSE:AGN opened at $157.72 on Thursday. The company has a quick ratio of 0.78, a current ratio of 0.92 and a debt-to-equity ratio of 0.32. Allergan plc has a 1 year low of $142.81 and a 1 year high of $197.00. The firm has a market cap of $55.27 billion, a P/E ratio of 9.65, a PEG ratio of 1.30 and a beta of 1.31.

Allergan (NYSE:AGN) last announced its quarterly earnings data on Tuesday, October 30th. The company reported $4.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.04 by $0.21. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The business had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.89 billion. During the same period last year, the company earned $4.15 earnings per share. Allergan’s quarterly revenue was down 3.0% compared to the same quarter last year. Analysts anticipate that Allergan plc will post 16.43 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 14th. Shareholders of record on Tuesday, November 13th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, November 9th. This represents a $2.88 annualized dividend and a yield of 1.83%. Allergan’s dividend payout ratio (DPR) is currently 17.61%.

ILLEGAL ACTIVITY WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2018/11/15/rhumbline-advisers-trims-stake-in-allergan-plc-agn.html.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Further Reading: Average Daily Trade Volume – What It Means In Stock Trading

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.